title: Brain delivery of NAP with PEG-PLGA nanoparticles modified with phage display peptides.
abstract: OBJECTIVE
  A phage-displayed peptide TGN was used as a targeting motif to help the delivery of NAP-loaded nanoparticles across the blood-brain barrier (BBB), which sets an obstacle for brain delivery of NAP in vivo.
  
  
  METHODS
  Intracerebroventricular injection of Aβ₁₋₄₀ into mice was used to construct in vivo model of Alzheimer's disease. The water maze task was performed to evaluate the effects of the NAP formulations on learning and memory deficits in mice. The neuroprotective effect was tested by detecting acetylcholinesterase (AChE) and choline acetyltransferase (ChAT) activity and conducting histological assays.
  
  
  RESULTS
  Intravenous administration of NAP-loaded TGN modified nanoparticles (TGN-NP/NAP) has shown better improvement in spatial learning than NAP solution and NAP-loaded nanoparticles in Morris water maze experiment. The crossing number of the mice with memory deficits recovered after treatment with TGN-NP/NAP in a dose dependent manner. Similar results were also observed in AChE and ChAT activity. No morphological damage and no detectable Aβ plaques were found in mice hippocampus and cortex treated with TGN-NP/NAP.
  
  
  CONCLUSIONS
  TGN modified nanoparticles could be a promising drug delivery system for peptide and protein drug such as NAP to enter the brain and play the therapeutic role.
authors.affiliation: Department of Pharmaceutics, School of Pharmacy, Fudan University, 826 Zhangheng Rd., Shanghai 201203, People's Republic of China.
authors.forename: Jingwei
authors.initials: J
authors.lastname: Li
authors.forename: Chi
authors.initials: C
authors.lastname: Zhang
authors.forename: Jing
authors.initials: J
authors.lastname: Li
authors.forename: Li
authors.initials: L
authors.lastname: Fan
authors.forename: Xinguo
authors.initials: X
authors.lastname: Jiang
authors.forename: Jun
authors.initials: J
authors.lastname: Chen
authors.forename: Zhiqing
authors.initials: Z
authors.lastname: Pang
authors.forename: Qizhi
authors.initials: Q
authors.lastname: Zhang
mesh_terms: D000110:Acetylcholinesterase / Q000378:metabolism; D000544:Alzheimer Disease / Q000188:drug therapy* / Q000473:pathology; D000818:Animals; D001812:Blood-Brain Barrier / Q000378:metabolism / Q000473:pathology; D001921:Brain / Q000187:drug effects / Q000473:pathology; D002795:Choline O-Acetyltransferase / Q000378:metabolism; D016503:Drug Delivery Systems; D008297:Male; D008569:Memory Disorders / Q000188:drug therapy; D051379:Mice; D053758:Nanoparticles / Q000737:chemistry* / Q000648:ultrastructure; D018696:Neuroprotective Agents / Q000008:administration & dosage* / Q000737:chemistry / Q000627:therapeutic use*; D009842:Oligopeptides / Q000008:administration & dosage* / Q000737:chemistry / Q000627:therapeutic use*; D011092:Polyethylene Glycols / Q000737:chemistry*; D011098:Polyglactin 910 / Q000737:chemistry*
chemical_list: D018696:Neuroprotective Agents; D009842:Oligopeptides; C102418:poly(lactic-glycolic acid)-poly(ethyleneglycol) copolymer; D011098:Polyglactin 910; D011092:Polyethylene Glycols; D002795:Choline O-Acetyltransferase; D000110:Acetylcholinesterase; C425904:davunetide
references.citation: J Mol Neurosci. 2002 Aug-Oct;19(1-2):167-70
references.pmid: 12212775
references.citation: Brain Res Dev Brain Res. 2003 Aug 12;144(1):83-90
references.pmid: 12888219
references.citation: Pharmacol Ther. 2007 May;114(2):146-54
references.pmid: 17363064
references.citation: Neurosci Lett. 2004 May 6;361(1-3):128-31
references.pmid: 15135910
references.citation: Am J Obstet Gynecol. 2003 Sep;189(3):790-3
references.pmid: 14526315
references.citation: Exp Neurol. 2012 Apr;234(2):521-6
references.pmid: 22245157
references.citation: Brain Res. 2002 Nov 1;954(1):42-50
references.pmid: 12393231
references.citation: Exp Neurol. 2009 Jan;215(1):153-9
references.pmid: 19013154
references.citation: J Neurochem. 1999 Mar;72(3):1283-93
references.pmid: 10037502
references.citation: CNS Drug Rev. 2005 Winter;11(4):353-68
references.pmid: 16614735
references.citation: J Neurochem. 2006 Aug;98(3):973-84
references.pmid: 16893427
references.citation: J Mol Neurosci. 2007;31(2):165-70
references.pmid: 17478890
references.citation: Neurosci Lett. 2008 Nov 28;446(1):30-5
references.pmid: 18822350
references.citation: Behav Brain Res. 2012 Jul 15;233(1):237-43
references.pmid: 22595040
references.citation: J Pharmacol Exp Ther. 2001 Jan;296(1):57-63
references.pmid: 11123362
references.citation: Biomaterials. 2011 Jul;32(21):4943-50
references.pmid: 21470674
references.citation: Proc Natl Acad Sci U S A. 2005 Mar 8;102(10):3811-6
references.pmid: 15728733
references.citation: Exp Gerontol. 2006 Apr;41(4):360-7
references.pmid: 16542809
references.citation: Neurochem Res. 2010 Jan;35(1):162-70
references.pmid: 19669875
references.citation: Nature. 2009 Feb 26;457(7233):1128-32
references.pmid: 19242475
references.citation: Peptides. 2007 Oct;28(10):2004-8
references.pmid: 17869381